Timothy M Dall1, Michael V Storm2, April P Semilla2, Neil Wintfeld3, Michael O'Grady4, K M Venkat Narayan5. 1. IHS Life Sciences, Washington, District of Columbia. Electronic address: tim.dall@ihs.com. 2. IHS Life Sciences, Washington, District of Columbia. 3. Novo Nordisk Inc. Plainsboro, New Jersey. 4. NORC at the University of Chicago, Illinois. 5. Rollins School of Public Health, Emory University, Atlanta, Georgia.
Abstract
BACKGROUND: The Community Preventive Services Task Force recommends combined diet and physical activity promotion programs for people at increased risk of type 2 diabetes, as evidence continues to show that intensive lifestyle interventions are effective for overweight individuals with prediabetes. PURPOSE: To illustrate the potential clinical and economic benefits of treating prediabetes with lifestyle intervention to prevent or delay onset of type 2 diabetes and sequelae. METHODS: This 2014 analysis used a Markov model to simulate disease onset, medical expenditures, economic outcomes, mortality, and quality of life for a nationally representative sample with prediabetes from the 2003-2010 National Health and Nutrition Examination Survey. Modeled scenarios used 10-year follow-up results from the lifestyle arm of the Diabetes Prevention Program and Outcomes Study versus simulated natural history of disease. RESULTS: Over 10 years, estimated average cumulative gross economic benefits of treating patients who met diabetes screening criteria recommended by the ADA ($26,800) or USPSTF ($24,700) exceeded average benefits from treating the entire prediabetes population ($17,800). Estimated cumulative, gross medical savings for these three populations averaged $10,400, $11,200, and $6,300, respectively. Published estimates suggest that opportunistic screening for prediabetes is inexpensive, and lifestyle intervention similar to the Diabetes Prevention Program can be achieved for ≤$2,300 over 10 years. CONCLUSIONS: Lifestyle intervention among people with prediabetes produces long-term societal benefits that exceed anticipated intervention costs, especially among prediabetes patients that meet the ADA and USPSTF screening guidelines.
BACKGROUND: The Community Preventive Services Task Force recommends combined diet and physical activity promotion programs for people at increased risk of type 2 diabetes, as evidence continues to show that intensive lifestyle interventions are effective for overweight individuals with prediabetes. PURPOSE: To illustrate the potential clinical and economic benefits of treating prediabetes with lifestyle intervention to prevent or delay onset of type 2 diabetes and sequelae. METHODS: This 2014 analysis used a Markov model to simulate disease onset, medical expenditures, economic outcomes, mortality, and quality of life for a nationally representative sample with prediabetes from the 2003-2010 National Health and Nutrition Examination Survey. Modeled scenarios used 10-year follow-up results from the lifestyle arm of the Diabetes Prevention Program and Outcomes Study versus simulated natural history of disease. RESULTS: Over 10 years, estimated average cumulative gross economic benefits of treating patients who met diabetes screening criteria recommended by the ADA ($26,800) or USPSTF ($24,700) exceeded average benefits from treating the entire prediabetes population ($17,800). Estimated cumulative, gross medical savings for these three populations averaged $10,400, $11,200, and $6,300, respectively. Published estimates suggest that opportunistic screening for prediabetes is inexpensive, and lifestyle intervention similar to the Diabetes Prevention Program can be achieved for ≤$2,300 over 10 years. CONCLUSIONS: Lifestyle intervention among people with prediabetes produces long-term societal benefits that exceed anticipated intervention costs, especially among prediabetespatients that meet the ADA and USPSTF screening guidelines.
Authors: Elizabeth Murray; Eric B Hekler; Gerhard Andersson; Linda M Collins; Aiden Doherty; Chris Hollis; Daniel E Rivera; Robert West; Jeremy C Wyatt Journal: Am J Prev Med Date: 2016-11 Impact factor: 5.043
Authors: Sarah M Bartsch; Elizabeth A Mitgang; Gail Geller; Sarah N Cox; Kelly J O'Shea; Angie Boyce; Sheryl S Siegmund; Jeffrey Kahn; Bruce Y Lee Journal: J Infect Dis Date: 2020-09-01 Impact factor: 5.226
Authors: Fang Chen; Wenqing Su; Shawn H Becker; Mike Payne; Cynthia M Castro Sweet; Anne L Peters; Timothy M Dall Journal: PLoS One Date: 2016-10-05 Impact factor: 3.240
Authors: Kimberly D Brunisholz; Molly B Conroy; Thomas Belnap; Elizabeth A Joy; Raj Srivastava Journal: J Healthc Qual Date: 2021 Mar-Apr 01 Impact factor: 1.028